Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence

Journal of the National Cancer Institute

Volumn 89, Issue 14, 1997, Pages 1027-1036

  Ziegler, Annemarie ^a   Luedke, Gerd H ^a   Fabbro, Doriano ^b   Altmann, Karl Heinz ^b   Stahel, Rolf A ^a   Zangemeister Wittke, Uwe ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA FRAGMENT; MESSENGER RNA; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER;

EID: 0030807543     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.14.1027     Document Type: Article

References (39)

1. Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer. In: DeVita VT Jr. Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol 1. 4th ed. Philadelphia: Lippincott, 1993:723-58.
2. Doyle LA. Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 1993;20:326-37.
3. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
4. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995;177:135-8.
5. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986;83:5214-8.
6. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
7. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996;271:12695-8.
8. Shimizu S, Eguchi Y, Kamiike W, Matsuda H, Tsujimoto Y. Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene 1996; 12:2251-7.
9. Nunez G, Seto M, Seremetis S, Ferrero D, Grignani F., Korsmeyer SJ, et al. Growth-and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 1989;86: 4589-93.
10. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994;54:3253-9.
11. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994;5 Suppl 1:61-5.
12. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8.
13. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-6.
14. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994;9:3049-55.
15. Smith MR, Abubakr Y, Mohammed R, Xie T, Hamdan M, al-Katib A. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 1995;2:207-12.
16. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995;9:131-8.
17. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994;4:71-9.
18. Froesch BA, Luedke GH, Ziegler A, Stahel RA, Zangemeister-Wittke U. The combined application of a doxorubicin immunoconjugate and bcl-2 antisense oligonucleotides on non-resistant and drug resistant small cell lung cancer cell lines. Tumor Targeting. In press.
19. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-12.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
21. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1989;7:43.
22. Cleveland DW, Lopata MA, MacDonald RJ, Cowan NJ, Rutter WJ, Kirschner MW. Number and evolutionary conservation of α-and β-tubulin and cytoplasmic β-and γ-actin genes using specific cloned cDNA probes. Cell 1980;20:95-105.
23. Hanada M, Krajewski S, Tanaka S, Cazals-Hatem D, Spengler BA, Ross RA, et al. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res 1993;53:4978-86.
24. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
25. Cotter TG, Lennon SV, Glynn JM, Green DR. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis [published erratum appears in Cancer Res 1992;52:3512]. Cancer Res 1992;52:997-1005.
26. Wagner RW. The state of the art in antisense research. Nat Med 1995;1: 1116-8.
27. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993;12:3679-84.
28. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
29. Lima WF, Monia BP, Ecker DJ, Freier SM. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 1992;31: 12055-61.
30. Bacon TA, Wickstrom E. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5′ cap region. Oncogene Res 1991;6:13-9.
31. Daaka Y, Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res 1990;5:267-75.
32. Blake KR, Murakami A, Miller PS. Inhibition of rabbit globin mRNA translation by sequence-specific oligodeoxyribonucleotides. Biochemistry 1985;24:6132-8.
33. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996;2:668-75.
34. Kitada S, Miyashita T, Tanaka S, Reed JC. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 1993;3: 157-69.
35. Webb A, Cunningham D, Cotter F, Clark P, di Stefano F, Ross P, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-41.
36. Kondo E, Nakamura S, Onoue H, Matsuo Y, Yoshino T, Aoki H, et al. Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. Blood 1992;80:2044-51.
37. Chleq-Deschamps CM, LeBrun DP, Huie P, Besnier DP, Warnke RA, Sibley RK, et al. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993;81: 293-8.
38. Harigai M, Miyashita T, Hanada M, Reed JC. A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. Oncogene 1996;12:1369-74.
39. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci U S A 1996;93:2239-44.